<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444677</url>
  </required_header>
  <id_info>
    <org_study_id>MB12066_002</org_study_id>
    <nct_id>NCT01444677</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single or Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yungjin Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KT&amp;G Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yungjin Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of MB12066 after a&#xD;
      single or multiple oral dose and to investigate the pharmacokinetic characteristics of&#xD;
      MB12066 after a single or multiple oral dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Safety/ Tolerability evaluation Adverse events, Physical examinations, Vital signs, ECG&#xD;
           (including continuous ECG monitoring), Laboratory tests (including hematology,&#xD;
           chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC&#xD;
&#xD;
        -  Pharmacokinetic Evaluation(single)&#xD;
&#xD;
             -  Serial blood samples and urine collections for pharmacokinetic evaluations will be&#xD;
                conducted between 0 (pre-dose) and 96 hours after a single oral dose.&#xD;
&#xD;
             -  Blood sampling time pre-dose, 0.5, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h,&#xD;
                48h, 72h post-dose&#xD;
&#xD;
             -  Urine collection time 0h - 6h, 6h - 12h, 12h - 24h, 24h - 48h, 48h - 72h&#xD;
&#xD;
             -  Evaluation parameters AUClast, AUCinf, Cmax, Tmax, t1/2, Vd/F, CL/F, Ae, fe, CLR&#xD;
&#xD;
        -  Pharmacokinetic Evaluation(multiple)&#xD;
&#xD;
             -  Serial blood samples and urine collections for pharmacokinetic evaluations will be&#xD;
                conducted after a single oral dose and Steady state.&#xD;
&#xD;
             -  Blood sampling time Day 1 pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h,&#xD;
                24h, Day3-6 Pre-dose, Day7 Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h,&#xD;
                24h, 36h, 48h, 72h, 96h post-dose&#xD;
&#xD;
             -  Urine collection time Day 1 Pre-dose, 0h - 6h, 6h - 12h, 12h - 24h, Day 7 Pre-dose,&#xD;
                0h - 6h, 6h - 12h, 12h - 24h&#xD;
&#xD;
             -  Evaluation parameters Cmax,ss, Cmin,ss, Cav,ss, AUCτ, Tmax,ss, t1/2, PTF(peak to&#xD;
                trough fluctuation ratio), fe, CLss/F, CLR&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (single dose)</measure>
    <time_frame>Single dose: from day-1 to day8-10</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with with Adverse Events (Multiple Dose)</measure>
    <time_frame>Multiple dose: from day-1 to day15-17</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Pharmacokinetic Evaluation (single dose)</measure>
    <time_frame>between 0 (pre-dose) and 72 hours after a single oral dose.</time_frame>
    <description>Single oral dose&#xD;
Blood sampling time pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h post-dose&#xD;
Urine collection time 0h - 6h, 6h - 12h, 12h - 24h, 24h - 48h, 48h - 72h&#xD;
Evaluation parameters Cmax,ss, Cmin,ss, Cav,ss, AUCτ, Tmax,ss, t1/2, PTF(peak to trough fluctuation ratio), fe, CLss/F, CLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Pharmacokinetic Evaluation (multiple dose)</measure>
    <time_frame>between 0 (pre-dose) and 24 hours and between 7day and 11 day after a multiple oral dose.</time_frame>
    <description>Multiple oral dose&#xD;
Blood sampling time Day 1 pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h post-dose Day 3-6 pre-dose Day 7 pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h, 96h post-dose&#xD;
Urine collection time Day 1 0h - 6h, 6h - 12h, 12h - 24h Day 7 0h - 6h, 6h - 12h, 12h - 24h&#xD;
Evaluation parameters Cmax,ss, Cmin,ss, Cav,ss, AUCτ, Tmax,ss, t1/2, PTF(peak to trough fluctuation ratio), fe, CLss/F, CLR</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>MB12066 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB12066 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB12066 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB12066 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 300mg(single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB12066</intervention_name>
    <description>MB12066 300mg</description>
    <arm_group_label>MB12066 300mg</arm_group_label>
    <other_name>beta-lapachone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB12066</intervention_name>
    <description>MB12066 400mg</description>
    <arm_group_label>MB12066 400mg</arm_group_label>
    <other_name>beta-lapachone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB12066</intervention_name>
    <description>MB12066 100mg</description>
    <arm_group_label>MB12066 100mg</arm_group_label>
    <other_name>beta-lapachone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB12066</intervention_name>
    <description>MB12066 200mg</description>
    <arm_group_label>MB12066 200mg</arm_group_label>
    <other_name>beta-lapachone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is informed of the investigational nature of this study and voluntarily agrees&#xD;
             to participate in this study and signs an Institutional Review Board (IRB) - approved&#xD;
             informed consent prior to performing any of the screening procedures&#xD;
&#xD;
          2. Healthy Korean male volunteers, age ranged 20 to 45 years (both inclusive)&#xD;
&#xD;
          3. A subject with body weight between 60 kg (inclusive) and 90 kg (exclusive) and body&#xD;
             mass index (BMI) between 18.5 (inclusive) and 25 (exclusive). ☞ BMI (kg/m2) = weight&#xD;
             (kg) / {height (m)}2&#xD;
&#xD;
          4. Findings within the range of clinical acceptability in medical history and physical&#xD;
             examination, and laboratory results within the laboratory reference ranges for the&#xD;
             relevant laboratory tests (unless the investigator considers the deviation to be&#xD;
             irrelevant for the purpose of the study)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A subject with history of allergies including drug allergies (aspirin, antibiotics,&#xD;
             etc.), or history of clinically significant allergies&#xD;
&#xD;
          2. A subject with clinical evidence or history of hepatic (including carrier of hepatitis&#xD;
             virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic,&#xD;
             oncologic, psychiatric, or cardiovascular disease&#xD;
&#xD;
          3. A subject with history of gastrointestinal disease or surgery (except simple&#xD;
             appendectomy or repair of hernia), which can influence the absorption of the study&#xD;
             drug&#xD;
&#xD;
          4. A subject whose hemoglobin(Hb) level &lt; 12 g/dL&#xD;
&#xD;
          5. A subject with fasting plasma glucose (FPG) level ≤ 70 mg/dL or ≥ 126 mg/dL&#xD;
&#xD;
          6. A subject with HbA1c level ≥ 7.0 %&#xD;
&#xD;
          7. A subject whose systolic blood pressure (SBP) ≤ 90 mmHg or ≥ 140 mmHg, diastolic blood&#xD;
             pressure (DBP) ≤ 40 mmHg or ≥ 90 mmHg or pulse rate (PR) ≥ 100 /min after at least 5&#xD;
             min sitting&#xD;
&#xD;
          8. A subject with history of drug abuse or positive urine drug screening test&#xD;
&#xD;
          9. A subject who has taken any prescribed medication or herbal compounds within 14 days&#xD;
             prior to the study drug administration. In addition, a subject who has taken any&#xD;
             over-the-counter drug or vitamin supplements within 7 days prior to the study drug&#xD;
             administration (However, investigators can judge the subject, who has taken the&#xD;
             medications during those periods above, eligible for the trial if all other conditions&#xD;
             are satisfied.)&#xD;
&#xD;
         10. A subject who has participated in any other clinical trial either for investigational&#xD;
             or marketed drugs within 8 weeks before the study drug administration&#xD;
&#xD;
         11. A subject who has donated or had loss of ≥ 400 mL of blood within 8 weeks prior to&#xD;
             start of administration of study drug&#xD;
&#xD;
         12. A subject who consumes more than 21 units of alcohol per week or unable to stop&#xD;
             drinking throughout the study period.&#xD;
&#xD;
         13. A smoker (except for whom quitted smoking prior to the drug administration for at&#xD;
             least 3 months)&#xD;
&#xD;
         14. A subject who heavily takes caffeine or caffeine-containing products, grapefruit,&#xD;
             grapefruit juice, grapefruit-containing products&#xD;
&#xD;
         15. A subject with unusual dietary habit&#xD;
&#xD;
         16. A subject who was previously assigned to treatment during this study&#xD;
&#xD;
         17. The investigator judges the subject not eligible for the study after reviewing&#xD;
             clinical laboratory results or other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Institute of Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Institute of Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Daehang-ro, Jongno-Gu</state>
        <zip>110-774</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beta-lapachone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

